Publicacións nas que colabora con Antonio Rivero Juárez (51)

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use

    Journal of Infection, Vol. 85, Núm. 3, pp. 322-326

2021

  1. Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain

    HIV Medicine, Vol. 22, Núm. 5, pp. 379-386

  2. Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 9, pp. 2375-2379

  3. Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

    Clinical Microbiology and Infection

2020

  1. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32

  2. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients

    AIDS (London, England), Vol. 34, Núm. 10, pp. 1497-1507

  3. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

  4. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 11, pp. 2810-2817

  5. Using machine learning methods to determine a typology of patients with HIVHCV infection to be treated with antivirals

    PLoS ONE, Vol. 15, Núm. 1

  6. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: A modeling analysis

    BMC Infectious Diseases, Vol. 20, Núm. 1

2019

  1. A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)

    Liver International, Vol. 39, Núm. 10, pp. 1918-1926

  2. Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes

    Journal of Hepatology

  3. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54

  4. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

    Scientific Reports, Vol. 9, Núm. 1

  5. Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection

    Scientific Reports, Vol. 9, Núm. 1

  6. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  7. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  8. Increasing importance of european lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain

    Eurosurveillance, Vol. 24, Núm. 9

  9. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients

    AIDS, Vol. 33, Núm. 2, pp. 269-278